CA
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVECOVER ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Published online before print December 20, 2007
CA Cancer J Clin 2008; 58:54-59
doi: 10.3322/CA.2007.0002
© 2008 American Cancer Society
This Article
Right arrow Full Text Freely available
Right arrow Full Text (PDF) Freely available
Right arrow Freely available CME: Take the course for this article:
 Utilizing the Tumor-Node-Metastasis Staging for Prostate Cancer: The Sixth ...
Right arrow All Versions of this Article:
CA.2007.0002v1
58/1/54    most recent
Right arrow Submit a letter to the editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Chang, S. S.
Right arrow Articles by Amin, M. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chang, S. S.
Right arrow Articles by Amin, M. B.

Utilizing the Tumor-Node-Metastasis Staging for Prostate Cancer

The Sixth Edition, 2002

Sam S. Chang, MD and Mahul B. Amin, MD

Dr. Chang is Associate Professor of Urologic Surgery, Vanderbilt University Medical Center, Nashville, TN.
Dr. Amin is Chairman, Department of Pathology & Laboratory Medicine, Cedars-Sinai Medical Center, Los Angeles, CA.

Published online through CA First Look at http://CAonline.AmCancerSoc.org.
To earn free CME credit for successfully completing the online quiz based on this article, go to http://CME.AmCancerSoc.org.

The Sixth Edition of the tumor-node-metastasis staging system for prostate cancer attempts to provide a helpful staging paradigm for clinicians. Accurate staging is critical not only for managing individual patients, but also for ascertaining trends in disease pattern in a large population of patients with prostate cancer. Several modifications have been made in an attempt to improve the cohesiveness and uniformity of patient evaluation and to aid in future meaningful clinical research. As data are accumulated and analysis continues, ongoing critical evaluation of this staging system will undoubtedly incorporate new evidence-based factors and bring about future refinements to prostate cancer staging.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVECOVER ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2008 by American Cancer Society.